Swiss Kareus Therapeutics Aims Its KU-046 at Alzheimer's

Undeterred by the recent string of high-profile failures in the field, Kareus Therapeutics SA moved its first-in-class drug candidate for Alzheimer's disease, KU-046, into a Phase I trial in healthy volunteers.